The life sciences industry value chain must transform to respond to changing wants and needs — now.
The future of healthcare is personal.
Today’s consumers are demanding personalized healthcare experiences. Traditional, reactive, one-size-fits-all therapies are no longer enough.
In the future, personalized, preventative and value-based care will be the norm. The consumer will demand outcome-centric therapeutics.
Biopharma and medical device companies that can achieve value chain transformation, adopt collaborative invention and embrace the consumerization of healthcare will gain a massive competitive edge. Those that don’t, will quickly become irrelevant.
To beat competitors and succeed in this market organizations must:
Innovation is key to staying competitive and flexible in a world where knowledge and sophisticated technologies are growing exponentially. Which is why it’s important to increase innovative capacity and capabilities with a flexible new business model that outsources and at the same time connects specific areas of the business such as research & discovery, clinical trials or manufacturing.
This results in lower, more predictable costs and the ability to leverage external expertise while simultaneously meeting regulatory requirements. What’s more, outsourcing clinical trials or manufacturing allows for more agile facilities and economies of scale while reducing time to market.
To help life sciences businesses achieve that goal, Dassault Systèmes’ 3DEXPERIENCE® platform connects the digital dots between you and your partner ecosystem – sharing data, knowledge and know-how in real-time for more productive relationships. You can expand your value network in an efficient, connected manner, allowing your company to use contractors and academics to greatest effect.
Customers and patients now expect more personalized healthcare solutions and experiences.
Delivering such value-added service lets you stand out in the marketplace. The answer is to use content and expertise to enhance your experience. The modeling, simulation, knowledge and expertise available from Dassault Systèmes makes this possible.
Dassault Systèmes has already demonstrated how it is done with the Living Heart Project. In this project, an ecosystem of experts collaborated using the 3DEXPERIENCE platform to create a virtual model of the human heart. The virtual model can be used for education, medical device design and testing, clinical diagnosis and regulatory science, ultimately paving the way for cutting edge innovations that will improve patient care. In addition, the Living Heart Project signed a five-year collaborative research agreement with the United States Food and Drug Administration (FDA) to spur medical device innovation by enabling innovative, new product designs.
As patients become more empowered to make their own healthcare decisions, they are demanding value. Hence the need for the life sciences industry to shift away from a product-driven model towards one that is value-based, where you are paid for positive outcomes. In this value-driven healthcare system, life sciences companies need to demonstrate real measurable value to the consumer.
With the 3DEXPERIENCE platform, you can truly create a sustainable and connected value network that leverages the data and analytics necessary to deliver value-driven products, while meeting all regulatory requirements.
It’s time to begin the transformation. Here’s how.
Propel your clinical trial into the digital age, stand up to stiff competition, and maintain strength in your therapeutic area. As a MEDIDATA partner, you work with the world’s leading clinical technology solutions, supported by dedicated experts focused on extending value and improving outcomes for your sponsor customers and their patients.
Our experts reveal how biopharma and medical devices companies can create a sustainable and connected value network to stand out in an increasingly consumerized healthcare market.